Next generation sequencing profiling identifies miR-574-3p and miR-660-5p as potential novel prognostic markers for breast cancer

Table 5 Univariate and multivariate results for recurrence free survival (Discovery cohort)

A. Case–control approach
Parameter	Univariate analysis		Multivariate analysis
Parameter	HR (95 % CI)	p-value	HR (95 % CI)	p-value
Risk score	1.95 (1.16 – 3.29)	0.01	2.27 (1.33 -3.88)	0.003
Tumor stage	0.42 (0.23 – 0.76)	0.01	0.34 (0.18 – 0.65)	0.001
Tumor grade	1.52 (0.88 – 2.63)	0.14
Age at diagnosis	1.02 (0.99 – 1.05)	0.29
TNBC status	0.75 (0.39 – 1.41)	0.37
B. Case-only approach Parameter
Parameter	Univariate analysis		Multivariate analysis
Parameter	HR (95 % CI)	p-value	HR (95 % CI)	p-value
Risk score	1.68 (0.99 – 2.82)	0.05	1.85 (1.09 – 3.14)	0.02
Tumor stage	0.42 (0.23 – 0.79)	0.01	0.38 (0.20 – 0.71)	0.003
Tumor grade	1.52 (0.88 – 2.63)	0.14
Age at diagnosis	1.02 (0.99 – 1.05)	0.29
TNBC status	0.75 (0.39 – 1.41)	0.37

A and B: The two and four miRNAs from Table 2A and B respectively were used to construct risk scores. Receiver Operating Characteristics Curve was used to dichotomize samples into low and high-risk groups. Univariate Cox proportional hazards regression model was run for risk score and for other clinical parameters. In the multivariate analysis, risk score was significant with p < 0.05 after adjusting for confounders.
HR Hazard Ratio; CI Confidence Interval; TNBC Triple Negative Breast Cancer

ISSN: 1471-2164